MedTrace Logo

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

NCT03293407 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2021-05-26

No results posted yet for this study

Summary

The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real life setting.

The study was not designed to investigate or confirm the effectiveness and safety of iloprost.

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

Iloprost (Ventavis, BAYQ6256)

Using Breelib device

DEVICE

Breelib nebulizer

Used for inhalation of Ventavis

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-10-09
Completion
2020-01-20

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03293407 on ClinicalTrials.gov